ArticlePharmaceutics2026
Palbociclib Capsule: A Bioequivalence Study in Healthy Subjects Under Fed Conditions to Compare Two Formulations.
Marcelo Gomes Davanço, Thaís Pereira Vespasiano, Jessé Moisan, Maira Eduarda Zanin, Gilberto Carlos Ruggiero Bernasconi, Marcia Aparecida Antonio, Oscar Gonzalez, Milesa Sarmiento, Mélanie Groleau
Abstract read
In one paragraphArticle in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Marcelo Gomes DavançoMedical & Clinical Affairs Department, United Medical Ltda. (a Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.ORCID 0000-0002-1684-6591 Thaís Pereira VespasianoMedical & Clinical Affairs Department, United Medical Ltda. (a Knight Therapeutics Company), Sao Paulo 04085-001, SP, Brazil.
Jessé MoisanMedical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.ORCID 0000-0002-2695-094X Maira Eduarda ZaninUnidade Integrada de Farmacologia e Gastroenterologia (UNIFAG), Universidade São Francisco, Bragança Paulista 12916-900, SP, Brazil.
Gilberto Carlos Ruggiero BernasconiUnidade Integrada de Farmacologia e Gastroenterologia (UNIFAG), Universidade São Francisco, Bragança Paulista 12916-900, SP, Brazil.
Marcia Aparecida AntonioUnidade Integrada de Farmacologia e Gastroenterologia (UNIFAG), Universidade São Francisco, Bragança Paulista 12916-900, SP, Brazil.ORCID 0000-0002-3239-509X Oscar GonzalezR&D Department, Laboratorio LKM S.A. (a Knight Therapeutics Company), Buenos Aires C1179, Argentina.
Milesa SarmientoR&D Department, Laboratorio LKM S.A. (a Knight Therapeutics Company), Buenos Aires C1179, Argentina.
Mélanie GroleauMedical & Clinical Affairs Department, Knight Therapeutics Inc., Montreal, QC H4M 2P2, Canada.
Funding
Knight Therapeutics CNSP0724
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
advanced breast cancerbioavailabilitybioequivalencegenericspalbociclibpharmacokinetics
Identifiers
PMID41754917
PMCPMC12944590
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390